Cerenome, Inc.
CNSYHealthcare|Medical - Pharmaceuticals|US
$0.64
-0.03 (-4.06%)
DCF Value
$2.01
Tangible Book / Share
$0.71
Cash / Share
$1.27
Financials
Financial Snapshot
Market Cap
$4.9M
Enterprise Value
$2.6M
Revenue (TTM)
$4.2M
Net Income (TTM)
-$26.1M
Cash & Investments
$8.6M
Net Cash
$8.5M
Free Cash Flow (TTM)
-$23.5M
Operating CF (TTM)
-$22.2M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$8.6M
Quarterly Burn
$5.5M
Monthly Burn
$1.8M
Est. Runway
~1.5 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $12.6M | $9.6M | $5.3M | $17.6M | $8.3M | $18.4M | $18.1M | $8.6M | $3.6M | $8.8M | $8.6M | |
| Operating Cash Flow | -$19.5M | -$18.1M | -$12.0M | -$5.9M | -$8.4M | -$10.3M | -$13.0M | -$12.9M | -$10.6M | -$20.8M | -$22.2M | |
| Free Cash Flow | -$19.6M | -$19.6M | -$12.1M | -$6.0M | -$8.9M | -$10.4M | -$13.7M | -$13.0M | -$10.7M | -$20.8M | -$23.5M | |
| Capital Expenditure | -$67.0K | -$1.5M | -$133.0K | -$67.0K | -$493.0K | -$144.0K | -$759.0K | -$160.0K | -$146.0K | -$67.0K | -$1.4M | |
| Financing Cash Flow | $17.6M | $16.8M | $7.2M | $12.6M | -$319.0K | $20.4M | $13.5M | $3.4M | $6.2M | $30.3M | $25.3M |
R&D Spending
R&D (TTM)
$12.5M
R&D Intensity
297.6%
R&D Growth vs Prior
+49.3%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.4M | $6.4M | $3.0M | $7.0M | $303.0K | $0.00 | $224.0K | $4.9M | $5.8M | $5.2M | $4.2M | |
| R&D Expense | $16.2M | $13.4M | $5.5M | $5.4M | $3.5M | $5.3M | $9.7M | $9.7M | $10.6M | $8.4M | $12.5M | |
| R&D % of Revenue | 142.3% | 208.5% | 185.1% | 76.7% | 1148.8% | — | 4329.5% | 197.2% | 181.7% | 160.7% | 297.6% | |
| SG&A | $12.2M | $11.2M | $6.2M | $5.3M | $6.4M | $6.9M | $9.5M | $8.5M | $9.9M | $12.1M | $17.9M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.4M | $6.4M | $3.0M | $7.0M | $303.0K | $0.00 | $224.0K | $4.9M | $5.8M | $5.2M | $4.2M | |
| Cost of Revenue | $2.7M | $1.3M | $1.1M | $0.00 | $2.7M | $66.0K | $712.0K | $9.7M | $852.0K | $445.0K | $438.0K | |
| Gross Profit | $8.7M | $5.1M | $1.8M | $7.0M | -$2.4M | -$66.0K | -$488.0K | -$4.8M | $5.0M | $4.8M | $3.8M | |
| R&D | $16.2M | $13.4M | $5.5M | $5.4M | $3.5M | $5.3M | $9.7M | $9.7M | $10.6M | $8.4M | $12.5M | |
| SG&A | $12.2M | $11.2M | $6.2M | $5.3M | $6.4M | $6.9M | $9.5M | $8.5M | $9.9M | $12.1M | $17.9M | |
| Operating Income | -$19.7M | -$20.7M | -$8.8M | -$3.7M | -$9.6M | -$12.5M | -$19.7M | -$13.3M | -$14.7M | -$15.3M | -$26.4M | |
| Interest Expense | $2.6M | $2.0M | $1.9M | $1.9M | $1.1M | $932.0K | $711.0K | $395.0K | $3.7M | $3.6M | $3.1M | |
| Pretax Income | -$22.0M | -$22.7M | -$8.9M | -$3.3M | -$8.2M | -$13.4M | -$20.3M | -$13.3M | -$13.0M | -$22.4M | -$26.1M | |
| Net Income | -$22.0M | -$22.7M | -$12.6M | -$10.9M | -$8.2M | -$13.4M | -$20.3M | -$13.3M | -$13.0M | -$22.4M | -$26.1M | |
| EPS (Diluted) | -240000000.00 | -131345500.00 | -32617500.00 | -3452500.00 | -697500.00 | -444500.00 | -288750.00 | -106000.00 | -58.50 | -7.19 | -4.43 | |
| EBITDA | -$18.3M | -$18.5M | -$6.6M | -$532.0K | -$8.4M | -$12.1M | -$18.9M | -$12.3M | -$8.4M | -$18.3M | -$22.4M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.31 | 3.11 | 6.77 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.6M | $9.6M | $5.3M | $17.6M | $8.3M | $18.4M | $18.1M | $8.6M | $76.0K | $8.8M | $2.4M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $3.5M | $0.00 | $6.2M | |
| Total Current Assets | $18.7M | $14.9M | $9.6M | $19.8M | $9.2M | $19.7M | $21.8M | $9.8M | $5.3M | $15.2M | $11.8M | |
| Total Assets | $34.6M | $31.6M | $24.0M | $23.2M | $12.1M | $22.0M | $23.9M | $11.4M | $6.6M | $16.3M | $14.0M | |
| Total Current Liabilities | $12.5M | $18.4M | $17.6M | $14.5M | $8.5M | $5.9M | $11.9M | $10.7M | $15.6M | $12.3M | $8.6M | |
| Long-Term Debt | $11.0M | $0.00 | $0.00 | $0.00 | $0.00 | $5.0M | $3.8M | $0.00 | $0.00 | $15.0K | $0.00 | |
| Total Liabilities | $23.6M | $18.6M | $18.8M | $22.1M | $9.1M | $11.1M | $17.4M | $12.7M | $15.6M | $12.3M | $8.6M | |
| Stockholders' Equity | $11.0M | $13.0M | $5.2M | $1.2M | $3.0M | $10.8M | $6.4M | -$1.3M | -$8.9M | $4.0M | $5.5M | |
| Retained Earnings | -$379.1M | -$401.7M | -$414.4M | -$425.3M | -$433.5M | -$446.9M | -$467.2M | -$480.5M | -$493.5M | -$515.9M | -$531.8M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.5M | -$18.1M | -$12.0M | -$5.9M | -$8.4M | -$10.3M | -$13.0M | -$12.9M | -$10.6M | -$20.8M | -$22.2M | |
| Capital Expenditure | -$67.0K | -$1.5M | -$133.0K | -$67.0K | -$493.0K | -$144.0K | -$759.0K | -$160.0K | -$146.0K | -$67.0K | -$1.4M | |
| Free Cash Flow | -$19.6M | -$19.6M | -$12.1M | -$6.0M | -$8.9M | -$10.4M | -$13.7M | -$13.0M | -$10.7M | -$20.8M | -$23.5M | |
| Investing Cash Flow | $64.0K | -$1.4M | -$133.0K | $5.6M | -$493.0K | -$82.0K | -$759.0K | -$160.0K | -$4.1M | -$854.0K | -$2.9M | |
| Financing Cash Flow | $17.6M | $16.8M | $7.2M | $12.6M | -$319.0K | $20.4M | $13.5M | $3.4M | $6.2M | $30.3M | $25.3M | |
| Issuance of Stock | $21.5M | $23.6M | $7.2M | $16.0M | $4.0M | $18.7M | $15.8M | $5.5M | $7.3M | $15.7M | $11.5M | |
| Repurchase of Stock | $0.00 | -$2.1M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$126.0K | -$374.0K | $0.00 | $220.0K | |
| Net Debt Issuance | $0.00 | -$4.7M | $0.00 | -$3.8M | -$5.4M | -$276.0K | -$1.6M | -$1.6M | -$704.0K | -$4.8M | $1.5M | |
| Stock Based Comp. | $1.1M | $753.0K | $355.0K | $127.0K | $247.0K | $606.0K | $606.0K | $569.0K | $550.0K | $1.5M | $3.1M | |
| Net Change in Cash | -$1.8M | -$2.3M | -$4.9M | $12.3M | -$9.2M | $10.1M | -$280.0K | -$9.6M | -$8.5M | $8.7M | $133.0K |
Dilution Tracker
Shares outstanding grew 25934766.7% over 5 years — significant dilution
Shares Outstanding
8M
5-Year Share Growth
+25934766.7%
Stock Issuance (TTM)
$11.5M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.31 | 3.11 | 6.77 | |
| Change vs Prior % | — | -97.5% | -97.3% | 696.1% | 225.1% | 166.7% | 118.8% | 80.0% | 244368.3% | 910.4% | 117.6% | |
| Stock Issuance | $21.5M | $23.6M | $7.2M | $16.0M | $4.0M | $18.7M | $15.8M | $5.5M | $7.3M | $15.7M | $11.5M | |
| Stock Repurchase | $0.00 | -$2.1M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$126.0K | -$374.0K | $0.00 | $220.0K | |
| Stock Based Comp. | $1.1M | $753.0K | $355.0K | $127.0K | $247.0K | $606.0K | $606.0K | $569.0K | $550.0K | $1.5M | $3.1M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 76.1% | 79.4% | 61.5% | 100.0% | -791.1% | — | -217.9% | -97.2% | 85.4% | 91.5% | 89.6% | |
| Operating Margin % | -173.2% | -322.6% | -293.7% | -52.3% | -3163.0% | — | -8800.0% | -271.1% | -252.3% | -293.5% | -628.1% | |
| Net Margin % | -193.7% | -353.9% | -423.5% | -155.6% | -2719.8% | — | -9051.3% | -271.0% | -222.8% | -429.4% | -620.7% | |
| EBITDA Margin % | -160.6% | -288.3% | -220.5% | -7.6% | -2784.5% | — | -8457.6% | -250.2% | -143.9% | -351.7% | -531.9% | |
| FCF Margin % | -172.2% | -306.1% | -405.9% | -85.4% | -2946.2% | — | -6129.9% | -264.8% | -183.7% | -399.8% | -560.3% | |
| ROE % | -200.7% | -174.5% | -241.8% | -938.5% | -271.9% | -123.7% | -314.6% | 987.8% | 145.0% | -560.2% | -394.2% | |
| ROA % | -63.7% | -71.8% | -52.7% | -46.9% | -68.1% | -61.0% | -84.9% | -116.9% | -195.7% | -137.1% | -185.9% | |
| ROIC % | -63.1% | -77.1% | -42.5% | -18.2% | -95.5% | -70.1% | -142.4% | -280.0% | 263.3% | -317.6% | -479.4% | |
| R&D / Revenue % | 142.3% | 208.5% | 185.1% | 76.7% | 1148.8% | — | 4329.5% | 197.2% | 181.7% | 160.7% | 297.6% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -2.4% | -43.7% | -53.5% | 134.6% | -95.7% | -100.0% | 0.0% | 2093.3% | 18.5% | -10.5% | |
| Gross Profit | 2.3% | -41.2% | -64.0% | 281.4% | -134.3% | 97.2% | -639.4% | -878.9% | 204.1% | -4.1% | |
| Operating Income | -28.9% | -5.0% | 57.6% | 58.3% | -162.1% | -30.3% | -57.8% | 32.4% | -10.3% | -4.1% | |
| Net Income | -17.6% | -2.9% | 44.3% | 13.8% | 24.3% | -62.6% | -51.3% | 34.3% | 2.5% | -72.5% | |
| EPS (Diluted) | 36.0% | 45.3% | 75.2% | 89.4% | 79.8% | 36.3% | 35.0% | 63.3% | 99.9% | 87.7% | |
| Operating Cash Flow | 4.6% | 7.2% | 33.9% | 50.7% | -42.8% | -21.9% | -26.2% | 0.9% | 17.9% | -96.8% | |
| Free Cash Flow | 7.1% | -0.1% | 38.3% | 50.7% | -49.5% | -16.8% | -31.7% | 5.2% | 17.8% | -94.8% | |
| R&D Expense | -14.8% | -17.5% | -58.7% | -2.9% | -35.1% | 52.9% | 82.2% | -0.1% | 9.2% | -20.8% | |
| SG&A Expense | -2.0% | -8.1% | -44.4% | -15.0% | 21.1% | 7.0% | 39.0% | -10.3% | 16.3% | 22.1% | |
| Total Assets | -8.2% | -8.7% | -24.1% | -3.2% | -47.9% | 81.6% | 8.6% | -52.3% | -41.8% | 146.1% | |
| Book Value / Share | 632.5% | 4716.8% | 1373.8% | -97.2% | -19.6% | 34.1% | -72.8% | -111.6% | 99.7% | 103.8% | |
| Debt | 5.7% | -22.8% | 4.2% | -15.7% | -41.6% | -0.0% | -17.7% | -27.4% | -19.5% | -75.6% | |
| Diluted Shares | -87.7% | -97.5% | -97.3% | 696.1% | 225.1% | 166.7% | 118.8% | 80.0% | 244368.3% | 910.4% |
Valuation
P/E (TTM)At Loss
P/S1.16
10Y Low / Med / High0.00 / 0.00 / 2.42
P/B0.80
10Y Low / Med / High0.00 / 0.00 / 3.15
EV/EBITDAAt Loss
10Y Low / Med / High0.16 / 0.65 / 10.49
EV/Revenue0.61
10Y Low / Med / High0.45 / 0.75 / 3.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$2.01
Tangible Book / Share
$0.71
Net Current Assets / Share
$0.42
Graham Net-Net
$0.20
Cash / Share
$1.27
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.08 | -0.56 | -0.00 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 | 2.42 | 1.16 | |
| P/B Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | -0.12 | 3.15 | 0.80 | |
| EV/EBITDA | -0.28 | -0.22 | -1.36 | 10.49 | 0.16 | 0.94 | 0.65 | 0.36 | -0.52 | -0.25 | -0.11 | |
| EV/Revenue | 0.45 | 0.64 | 3.00 | -0.80 | -4.46 | 0.00 | -55.20 | -0.89 | 0.75 | 0.90 | 0.61 |
Analyst Estimates & Quality
Altman Z-Score
-57.51
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $3.9M | $20.2M | $45.6M |
| Net Income | -$13.8M | -$7.7M | -$1.0M |
| EPS | $-4.43 | $-2.48 | $-0.33 |
| # Analysts (EPS) | 1 | 2 | 1 |